Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from China’s NMPA for Melanoma Treatment

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment o...

April 02, 2025 | Wednesday | News
Merck Exercises Global Commercialization Option for Pimicotinib, Marking a Milestone in Partnership with Abbisko Therapeutics

Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fe...

April 01, 2025 | Tuesday | News
Akeso Advances Global Leadership in Bispecific Antibodies with Approvals for Ivonescimab and Cadonilimab

Akeso Inc. (9926.HK), a leading biopharmaceutical company, has announced major advancements in its antibody drug pipeline, underscoring a transformative ...

March 31, 2025 | Monday | News
China Grants Breakthrough Therapy Designation to Innovent’s IBI363 for Hard-to-Treat Melanoma

Innovent Biologics, Inc.  a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the trea...

March 31, 2025 | Monday | News
Junshi Biosciences' Toripalimab (LOQTORZI®) Approved in Singapore for First-Line Treatment of Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

March 27, 2025 | Thursday | News
Sichuan Kelun-Biotech Secures Approval for First Radionuclide-Drug Conjugate (RDC) Clinical Trial in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the inve...

March 26, 2025 | Wednesday | News
ICP DAS-BMP Showcases Medical-Grade TPU for Ureteral Stents at CMEF 2025

ICP DAS-BMP (Biomedical Polymers), a committed Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is excited to...

March 25, 2025 | Tuesday | News
Shanghai Junshi Biosciences' Toripalimab Receives NMPA Approval for First-Line Treatment of Metastatic Liver Cancer

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

March 24, 2025 | Monday | News
AstraZeneca Announces $2.5 Billion Investment to Establish Sixth Global R&D Centre in Beijing

AstraZeneca announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manu...

March 24, 2025 | Monday | News
Rhythm Pharmaceuticals Reacquires Rights to IMCIVREE® (setmelanotide) in China, Hong Kong, and Macau

 Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neur...

March 24, 2025 | Monday | News
Innovent & HUTCHMED Report Positive FRUSICA-2 Trial Results for Advanced RCC

 Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treat...

March 19, 2025 | Wednesday | News
Doer Bio Completes Phase 2 Enrollment for DR10624 Tri-Agonist in Severe Hypertriglyceridemia

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...

March 10, 2025 | Monday | News
Akeso’s Ivonescimab Phase III Study Results Published in The Lancet, Paving the Way for New NSCLC Treatment

Akeso, Inc. is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VE...

March 07, 2025 | Friday | News
CARsgen Therapeutics Initiates First Patient Dosing of KJ-C2219 in Systemic Lupus Erythematosus Trial

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,...

February 28, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close